April 18, 2006 -- Amgen released its Q1 quarterly report, showing slightly better than expected profit numbers but about $100 million light on revenue; Bruker BioSciences will pay $135 million to bring in-house a sister company, Bruker Optics, which provides mass spectrometry tools; CombinatoRx offered positive Phase II data of an asthma drug as proof of concept of its corporate clinical plan; Britain refused to approve Exubera, the inhaled insulin drug from Pfizer, because it was no more effective than existing treatments, but cost more; an osteoporosis drug from Lilly is just as effective as tamoxifen against breast cancer, but causes fewer side effects; Neurochem filed for approval of Fibrillex, a treatment for Amyloid A amyloidosis; MGI Pharma published data from its Phase III study of Dacogen, an injection for myelodysplastic syndromes; ArQule received a milestone payment from Wyeth, a result of filing for Investigational New Drug status for their Alzheimer’s disease drug. The Centient Biotech 200™ climbed 36.5 points to 3837.55, a gain of .96%. More details...
